Oragenics, Inc.
12085 Research Drive
Alachua
Florida
32615
United States
202 articles with Oragenics, Inc.
-
Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE
3/14/2023
Oragenics, Inc. today reports favorable findings from third party laboratory testing of several compounds in Oragenics’ lantibiotics platform to combat multiple pathogens despite the resistance of those pathogens to standard-of-care antibiotics.
-
Oragenics Appoints Janet Huffman as Chief Financial Officer Strengthening Executive Leadership Team
3/8/2023
Oragenics, Inc., a biotechnology company dedicated to fighting infectious diseases including COVID-19, announces the appointment of Janet Huffman as Chief Financial Officer, effective March 7, 2023.
-
Oragenics Enters into an Exclusive Global License Agreement with Inspirevax to Develop Intranasal Covid Vaccine Candidate
3/1/2023
Oragenics, Inc. today announced that the Company has entered into an exclusive global license agreement with Inspirevax Inc. for its novel intranasal mucosal adjuvant, BDX301.
-
Oragenics, Inc. Regains Compliance with NYSE American
2/3/2023
Oragenics, Inc. today announced that the Company has received formal notice from the NYSE American, LLC (“NYSE American”) stating that the Company has regained compliance with the NYSE American’s continued listing standards.
-
Oragenics, Inc. Discloses One-for-Sixty Reverse Stock Split
12/23/2022
Oragenics, Inc. announced that its Board of Directors on December 22, 2022 approved a 1-for-60 reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.001 per share, accompanied by a corresponding decrease in the Company’s authorized shares of common stock, such that, following the consummation of the Reverse Stock Split, the number of authorized shares of common stock will be reduced from 250,000,000 shares to 4,166,666 shares.
-
Oragenics Reports Favorable Toxicology Results for its COVID-19 Intranasal Vaccine Candidate
12/22/2022
Oragenics, Inc. today announced results indicating no toxicity signals or adverse events from its Good Laboratory Practices (GLP) toxicology study in rabbits evaluating the safety and immunogenicity of its NT-CoV2-1 intranasal vaccine candidate.
-
Oragenics, Inc. Receives NYSE American Notice
12/20/2022
Oragenics, Inc., a biotech company dedicated to fighting infectious diseases including COVID-19, announced that it received a Notice on December 19, 2022 from the NYSE American LLC stating that the Company is not in compliance with the continued listing standards as set forth in Section 1003 of the NYSE American Company Guide.
-
Oragenics, Inc. Announces New Chair - December 19, 2022
12/19/2022
Oragenics, Inc., a biotech company dedicated to fighting infectious diseases including COVID-19, announced that on December 16, 2022 the Board of Directors appointed Charles Pope as its Chairman of the Board of Directors succeeding Dr. Frederick W. Telling, who has served as a director since June 2010 and as Chairman since February 2011.
-
Oragenics to Participate in the 2022 BioFlorida Annual Conference
10/24/2022
Oragenics, Inc., a biotech company dedicated to fighting infectious diseases including COVID-19, announces its participation in the 2022 BioFlorida Annual Conference, being held November 2-4 in Miami.
-
Oragenics Issues Letter to Shareholders - September 30, 2022
9/30/2022
Oragenics, Inc., a biotech company dedicated to fighting infectious diseases including coronaviruses, issued the following letter to shareholders from its President and Chief Executive Officer, Kim Murphy.
-
Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate
8/24/2022
Oragenics, Inc. today announced favorable preliminary results from its ongoing Good Laboratory Practice (GLP) toxicology study to evaluate the safety profile and immunogenicity of its NT-CoV2-1 vaccine candidate in rabbits.
-
SARS-CoV-2 typically enters the body via the nose or mouth. Because of this, many think a nasal spray vaccine would do a better job of preventing COVID-19 infection and cutting transmission than an injection.
-
Oragenics Appoints Seasoned Vaccine Executive Kimberly Murphy as President and Chief Executive Officer
6/23/2022
Oragenics, Inc., a biotech company dedicated to fighting infectious diseases including coronaviruses, announces the appointment of Ms. Kimberly M. Murphy, member of the Board of Directors, as President and Chief Executive Officer effective June 23, 2022.
-
COVID-19 Research: Paxlovid Disappoints in Standard-Risk Setting, Nasal Spray Offers New Hope
6/15/2022
Biopharma has been stepping up research and drug development against COVID-19 -though results haven't always been encouraging. Here are the latest stories from this space: -
Oragenics Announces Publication of Positive Data for its NT-CoV2-1 Intranasal COVID-19 Vaccine Candidate in Scientific Reports
6/14/2022
Oragenics Announces Publication of Positive Data for its NT-CoV2-1 Intranasal COVID-19 Vaccine Candidate in Scientific Reports.
-
Oragenics to Participate at the World Vaccine Congress Washington 2022
4/18/2022
Oragenics, Inc. announced that Kimberly Murphy, a member of the Company’s Board of Directors, will attend the upcoming World Vaccine Congress Washington that will be held on April 18-22 to showcase the Company’s lead product, NT-CoV2-1, an intranasal vaccine candidate, and to pursue business development opportunities.
-
Oragenics Initiates a Pivotal IND-Enabling Toxicology Study on its Intranasal COVID-19 Vaccine Candidate, NT-CoV2-1
3/22/2022
Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) today announced the initiation of a Good Laboratory Practice (GLP) toxicology study to evaluate the safety profile and immunogenicity of its NT-CoV2-1 vaccine candidate in rabbits.
-
Oragenics Engages KBI Biopharma to Support Development of Intranasal COVID-19 Vaccine Candidate NT-CoV2-1
3/10/2022
Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) today announced it has entered into an agreement with KBI Biopharma, Inc. (“KBI”) for the process transfer, process optimization and cGMP manufacturing of the Company’s intranasal vaccine candidate NT-CoV2-1.
-
Oragenics Extends Collaboration with the National Research Council of Canada to Develop Vaccine against the Omicron Variant
12/20/2021
Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) today announced it has extended a licensing and collaboration agreement with the National Research Council of Canada (NRC) that will enable Oragenics to pursue an intranasal vaccine designed to protect against the SARS-CoV-2 Omicron variant.
-
Oragenics to Participate in Virtual Fireside Chat Hosted by Alliance Global Partners
12/9/2021
Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) today announced that the Company will participate in Alliance Global Partners’ (AGP) Virtual Series on Tuesday December 14, 2021 at 1:00 p.m. Eastern time.